KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Leases (2016 - 2025)

Historic Current Leases for Rigel Pharmaceuticals (RIGL) over the last 14 years, with Q3 2025 value amounting to $594000.0.

  • Rigel Pharmaceuticals' Current Leases rose 2746.78% to $594000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $594000.0, marking a year-over-year increase of 2746.78%. This contributed to the annual value of $285000.0 for FY2024, which is 5881.5% down from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Current Leases stood at $594000.0 for Q3 2025, which was up 2746.78% from $517000.0 recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Current Leases registered a high of $9.9 million during Q4 2021, and its lowest value of $285000.0 during Q4 2024.
  • Its 5-year average for Current Leases is $3.3 million, with a median of $692000.0 in 2023.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Current Leases tumbled by 9458.78% in 2023 and then soared by 5790.65% in 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' Current Leases (Quarter) stood at $9.9 million in 2021, then plummeted by 88.55% to $1.1 million in 2022, then plummeted by 38.92% to $692000.0 in 2023, then plummeted by 58.82% to $285000.0 in 2024, then surged by 108.42% to $594000.0 in 2025.
  • Its last three reported values are $594000.0 in Q3 2025, $517000.0 for Q2 2025, and $456000.0 during Q1 2025.